ESR1 and breast carcinoma: They also used ER + pre—clinical breast cancer models, including those with wild—type (WT) and mutated ESR1, to confirm that ER degradation can hinder tumor growth, suggesting vepdegestrant might be a more effective foundation for estrogen therapy for ER +/HER2—breast cancer patients.